Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
Earnings Data
Report Date
May 20, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.73Last Year’s EPS
-0.25Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: -12.07%
|Next Earnings Date:May 20, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and financial stability but also noted substantial operational losses and high instances of mild injection site reactions in a new formulation study.Company Guidance
During the Fiscal Year 2024 conference call, Acumen Pharma provided several key metrics and updates on their Alzheimer's drug development. The company's Phase 2 clinical trial, ALTITUDE AD, successfully completed enrollment with 542 participants, ahead of schedule, marking a significant milestone. This trial focuses on evaluating the efficacy of sabirnetug, with a primary endpoint of change from baseline to 18 months on the Integrated Alzheimer's Disease Rating Scale (iADRS). The trial also includes secondary measures such as the CDR Sum of Boxes and various biomarkers. Financially, Acumen ended 2024 with $231.5 million in cash and securities, expecting this to fund operations into the first half of 2027. R&D expenses rose to $93.8 million, primarily due to the ALTITUDE AD trial, while G&A expenses remained steady at $20.2 million, culminating in a net loss of $102.3 million for the year. The company anticipates sharing top-line results from ALTITUDE AD in late 2026 and is also advancing a subcutaneous formulation of sabirnetug following promising Phase 1 results.Completion of ALTITUDE AD Phase 2 Enrollment
Acumen Pharma successfully completed enrollment of 542 participants in the ALTITUDE AD Phase 2 study ahead of schedule, demonstrating the team's ability to exceed enrollment goals.
Subcutaneous Formulation Development
The Phase 1 study investigating subcutaneous administration of sabirnetug was completed. Results showed it was well-tolerated, with systemic exposure supporting continued development, providing important optionality for patients.
Financial Position
Acumen ended 2024 with $231.5 million in cash and marketable securities, expected to support clinical and operational activities into the first half of 2027.
---
ABOS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ABOS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $1.16 | $1.23 | +6.03% |
| Nov 12, 2024 | $3.22 | $2.68 | -16.77% |
| Aug 13, 2024 | $2.56 | $2.77 | +8.20% |
| May 14, 2024 | $3.36 | $3.69 | +9.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Acumen Pharmaceuticals (ABOS) report earnings?
Acumen Pharmaceuticals (ABOS) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.
What is Acumen Pharmaceuticals (ABOS) earnings time?
Acumen Pharmaceuticals (ABOS) earnings time is at May 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABOS EPS forecast?
ABOS EPS forecast for the fiscal quarter 2025 (Q1) is -0.73.
---